



Announcement Summary

Entity name

STARPHARMA HOLDINGS LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday November 15, 2023

The +securities to be quoted are:

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
SPL	ORDINARY FULLY PAID	20,880	09/11/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

STARPHARMA HOLDINGS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

078532180

1.3 ASX issuer code

SPL

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

15/11/2023



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

2.2 The +securities to be quoted are:

☒ Additional +securities in a class that is already quoted on ASX ("existing class")



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class issued under an +employee incentive scheme

FROM (Existing Class)

ASX +security code and description

SPLAK : PERFORMANCE RIGHT

TO (Existing Class)

ASX +security code and description

SPL : ORDINARY FULLY PAID

Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

20,880

Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://starpharma.com/assets/asxannouncements/201019%20SPL%202020%20Notice%20of%20AGM.pdf>

Are any of these +securities being issued to +key management personnel (KMP) or an +associate

☒ No

Issue date

9/11/2023

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes



Issue details

Number of +securities to be quoted

20,880

Are the +securities being issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

Securities being issued are on conversion of vested employee performance rights to ordinary shares at no cost.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

Additional amount of 20,880 vested employee performance rights to be issued as ordinary shares are in addition to the recent conversion of vested employee performance rights to ordinary shares lodged on 10 November 2023 via Appendix 2A .

**Part 4 - Issued capital following quotation**

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
SPL : ORDINARY FULLY PAID	411,703,964

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
SPLAK : PERFORMANCE RIGHT	23,073,665



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

☒ Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13